Regeneron Pharmaceuticals, Inc. REGN
At closeNov 12, 2026, 5:24 PM EST
After hours · Nov 12, 5:24 PM ET
- YTD
- +23.23%
- 1 year
- +39.53%
- Market cap
- 98.40B
- Revenue (ttm)
- 16.90B
- Profit margin
- 28.51%
- EPS (ttm)
- 45.24
- Shares out
- 101.63M
- P/E ratio
- 21.03
- Forward P/E
- 13.45
- Dividend
- 3.76 (0.41%)
- Ex-dividend date
- Nov 19, 2026
- YTD return
- +23.23%
- 1-year return
- +39.53%
- Volume
- 1.03M
- Avg volume
- 778.46K
- Open
- 971.85
- Previous close
- 959.41
- Day's range
- 944.71 – 981.55
- 52-week range
- 591.52 – 991.73
- Beta
- 0.10
- Analysts
- Buy
- Price target
- 977.93 (+2.8%)
- Earnings date
- Jan 28, 2027
5D +47.22 (+5.22%)
Key statistics
- Enterprise value
- 89.68B
- PEG ratio
- 1.17
- Price / sales
- 5.82
- Price / book
- 2.85
- Dividend yield
- 0.39%
- Payout ratio
- 8.18%
- Revenue growth
- 36.30%
- Free cash flow
- 2.58B
- Total cash
- 9.30B
- Total debt
- 2.71B
- Return on equity
- 14.95%
- Short % of float
- 2.27%
- 50-day average
- 811.95
- 200-day average
- 744.87
Analyst view
Consensus: buy
- Target (low)
- 812.00
- Target (mean)
- 977.93
- Target (high)
- 1,175.00
- Strong buy4
- Buy15
- Hold9
- Sell0
- Strong sell0
Next earnings
Jan 28, 2027
Expected Jan 28, 2027. Consensus EPS estimate 25.39.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 28, 2027 | Dec 30, 2026 | 25.39 | — | — | — |
| Oct 30, 2026 | Sep 30, 2026 | 16.51 | 20.07 | +3.56 | +21.56% |
| Jul 30, 2026 | Jun 30, 2026 | 10.16 | 14.29 | +4.13 | +40.65% |
| Apr 29, 2026 | Mar 31, 2026 | 8.91 | 9.47 | +0.56 | +6.29% |
| Jan 30, 2026 | Dec 31, 2025 | 10.74 | 11.44 | +0.70 | +6.52% |
| Oct 28, 2025 | Sep 30, 2025 | 9.65 | 11.83 | +2.18 | +22.59% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | Leerink Partners | main | Market Perform | Market Perform |
| Nov 2, 2026 | Bernstein | main | Market Perform | Market Perform |
| Nov 2, 2026 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
| Nov 2, 2026 | Truist Securities | main | Buy | Buy |
| Nov 2, 2026 | RBC Capital | main | Sector Perform | Sector Perform |
| Nov 2, 2026 | Guggenheim | main | Buy | Buy |
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. It has a strategic alliance with Sanofi to develop long-acting immunology antibodies. The company was incorporated in 1988 and is based in Tarrytown, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- regeneron.com
News
POTS Phase 2 Trial Shows Baloncibart, a First-in-Class NPR1 Blocking Antibody, Reduced Orthostatic Heart Rate and Improved Orthostatic Symptoms 
If You Invested $1000 In Regeneron Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today 
REGN Soars 27.4% in a Month: Buy, Sell or Hold the Stock? 
Why Regeneron (REGN) is a Top Value Stock for the Long-Term 
Brightview Posts Downbeat Q4 Results, Joins Astronics, Spire Global And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session 
Regeneron Pharmaceuticals, Inc. (REGN) Discusses Genetic Center and CIDEB siRNA Development for MASH Transcript 
Amgen vs. Regeneron: Higher Dividends Now or Bigger Growth Later? 
Regeneron Pharmaceuticals Advances Liver Drug After Early Trial Cuts Liver Fat by Up to 80% 
Alnylam And Regeneron Says Data Published In The The New England Journal Of Medicine, Reports Up To 80% Reduction In Liver Fat Sustained For 36 Weeks After Single CIDEBsiRNA Dose In MASLD Patients 
3 Biotech Stocks That Actually Pay Dividends and Keep Raising Them
Your note
Sign in to keep a note on REGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BROWN MICHAEL S | Director | Sale | Oct 29, 2026 | 12,865 |
| FENIMORE CHRISTOPHER R | Chief Financial Officer | Stock Gift | Nov 1, 2026 | 25,249 |
| LAROSA JOSEPH J | General Counsel | Sale | Nov 1, 2026 | 44,726 |
| MCCOURT MARION E | Officer | Sale | Oct 29, 2026 | 11,090 |
| MURPHY ANDREW J | Officer | Stock Award(Grant) | Dec 4, 2025 | 56,437 |
| RYAN ARTHUR F. | Director | Sale | Jul 1, 2026 | 17,303 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 8.97% | 9,113,506 | 8.67B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 6.52% | 6,629,759 | 6.31B | Jun 29, 2026 |
| Dodge & Cox Inc. | 4.79% | 4,871,137 | 4.63B | Jun 29, 2026 |
| State Street Corporation | 4.76% | 4,834,688 | 4.60B | Jun 29, 2026 |
| Invesco Ltd. | 3.88% | 3,940,665 | 3.75B | Jun 29, 2026 |
| JPMORGAN CHASE & CO | 3.71% | 3,774,199 | 3.59B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 3.22% | 3,270,896 | 3.11B | Jun 29, 2026 |
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 3.07% | 3,121,304 | 2.97B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.55% | 2,588,231 | 2.46B | Jun 29, 2026 |
| Invesco QQQ Trust, Series 1 | 2.08% | 2,112,569 | 2.01B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.29% | 1,306,480 | 1.24B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.25% | 1,274,099 | 1.21B | Sep 29, 2026 |